SecBot SecBot
SECBOTREPLAY Home › Report › IOVA

IOVA · Iovance Biotherapeutics received marketing authorization from the…

IOVANCE BIOTHERAPEUTICS, INC. · 8-K filed Jun 10, 2026 at 17:01 ET

At the news

BULLISHIMPACT 7/10

8-K filed Jun 10, 2026 at 17:01 ET

Iovance Biotherapeutics received marketing authorization from the Australian TGA for Amtagvi (lifileucel) for advanced melanoma, marking its third regulatory approval and expanding into a market with the highest global melanoma incidence. Shareholders also approved an increase in authorized common shares from 500M to 650M, providing flexibility for future capital needs.

  • Received TGA (Australia) marketing authorization for Amtagvi in advanced melanoma, the company's third global approval
  • Australia has the highest rate of melanoma globally with ~17,000 new cases annually
  • Shareholders approved increasing authorized common shares from 500M to 650M
  • Company is authorizing its first Australian treatment center and advancing expansion strategy

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access